IL18 and Myocardial fibrosis: In summary, BYHWD exerts anti-inflammatory effects by down-regulating the expression of inflammatory factors such as IL-6, IL-1β, IL-18, and NLRP3, and inhibiting the JAK/STAT and TLR4/NF-κB signaling pathways, thereby slowing down the process of myocardial fibrosis.